Related Experiment Videos
Opioid antagonist impedes exposure
T V Merluzzi1, C B Taylor, M Boltwood
1University of Notre Dame.
Journal of Consulting and Clinical Psychology
|June 1, 1991
Summary
Exposure therapy for phobias may involve endorphins. Blocking these with naltrexone (an opioid antagonist) led to more dropouts and slower progress in spider-phobic individuals during exposure treatment.
Area of Science:
- Psychology
- Neuroscience
- Pharmacology
Background:
- Exposure therapy is a recognized treatment for simple phobias.
- The role of endogenous opioid system in phobia treatment is not fully understood.
Purpose of the Study:
- To investigate the involvement of endorphin release in exposure therapy for spider phobia.
- To examine the effects of naltrexone, an opioid antagonist, on exposure treatment outcomes.
Main Methods:
- Thirty participants with spider phobia underwent graded exposure tasks.
- Participants were randomly assigned to receive either naltrexone or a placebo.
- Physiological (heart rate, blood pressure) and psychological (anxiety, self-efficacy, cognitions) measures were collected.
Main Results:
- The naltrexone group exhibited significantly higher dropout rates and took longer to complete treatment steps.
- Participants receiving naltrexone showed greater maximum heart rate and anxiety levels at a key treatment point.
- No significant differences were observed in self-efficacy or cognitive measures between groups.
Conclusions:
- Findings suggest the endogenous opioid system plays a role in the efficacy of exposure therapy.
- Opioid system modulation may impact treatment adherence and symptom reduction during exposure.